Akèy › Sindrom Sjogren
Etid klinik pou Sindrom Sjogren ap rekrite nan Etazini
16 etid pou Sindrom Sjogren ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX6 etid
- Washington, DC5 etid
- Boston, MA5 etid
- Charlotte, NC4 etid
- Tampa, FL4 etid
- Arlington, TX4 etid
- Cicero, IL4 etid
- Dallas, TX3 etid
- Orlando, FL3 etid
- Cypress, TX3 etid
- Kansas City, MO3 etid
- Chicago, IL3 etid
- Tucson, AZ3 etid
- Clearwater, FL3 etid
- Warren, MI3 etid
Pa eta
- Arizona4 etid
- Florid7 etid
- Illinois5 etid
- Kalifòni5 etid
- Maryland6 etid
- Massachusetts5 etid
- Michigan3 etid
- Missouri3 etid
- New York3 etid
- North Carolina6 etid
- Ohio3 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas8 etid
- Virginia3 etid
- Washington3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07281456The Pathogenesis and Natural History of Sjogren's Disease
Ap rekriteEtid obsèvasyon
Laj 16 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT01425892Characterization of Diseases With Salivary Gland Involvement
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 4 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT02327884Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07621809A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 25, 2026 · NCT07737743Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 27, 2026 · NCT07404865Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Ap rekriteFaz 1
Laj 18 a 90 · Tout sèks · Mizajou Aug 19, 2026 · NCT06392711A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT07041099Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders
Ap rekrite
Laj 18 a 100 · Tout sèks · Mizajou Aug 10, 2026 · NCT07180537AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 28, 2026 · NCT06747949Rheumatology Patient Registry and Biorepository
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 99 · Tout sèks · Mizajou Feb 13, 2026 · NCT04402086Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Fanm · Mizajou Jan 8, 2026 · NCT03276923The Myelin Disorders Biorepository Project
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 23, 2025 · NCT03047369Rheumatology Diet Study
Ap rekriteEtid obsèvasyon
Laj 18 a 65 · Tout sèks · Mizajou Dec 6, 2024 · NCT06339957Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.